Pyxis Oncology appointed Thomas Civik permanent Chief Executive Officer and Chairman of the Board effective September 4, 2026. Civik had served as interim CEO since February 2 and has been a director since 2021….
Mirum Pharmaceuticals appointed Rob Myers, M.D., chief medical officer effective September 21, 2026. He succeeds Joanne Quan, M.D., who is departing; the company did not disclose her effective departure date, reason, next destination or…
Editas Medicine appointed Dan Ory, M.D., chief medical officer effective September 8, 2026. He will oversee clinical-development strategy and operations as EDIT-401 approaches clinical development for hyperlipidemia and will support the broader in-vivo gene-editing…
Vaxcyte appointed Luis Jodar as chief medical officer as its 31-valent pneumococcal conjugate vaccine, VAX-31, approaches Phase III adult readouts and a planned biologics-license application. Jodar previously spent 17 years at Pfizer and most…
Allogene Therapeutics said Executive Vice President and Chief Financial Officer Geoffrey Parker will retire in all capacities effective November 6, 2026. He will continue leading finance through that date while the company conducts an…
Beam Therapeutics appointed Eric Foster as chief commercial officer to lead commercial organization and strategy across its hematology and genetic-disease franchises. Beam explicitly linked the role to preparations for a potential 2027 launch of…
TELA Bio disclosed that Roberto Cuca stepped down as chief financial officer, chief operating officer, corporate secretary and principal financial officer effective August 31. The filing treats the departure as a termination without cause….
Invivyd appointed board chair Marc W. Elia chief executive officer and principal executive officer, effective August 30. CFO William Duke Jr., who previously held the principal-executive-officer designation, remains CFO, principal financial officer and principal…
Vivace Therapeutics named Craig Gibbs as chief executive officer and appointed Ellen Lubman as chief business and strategy officer, formalizing a leadership transition from founder Sofie Qiao as the company advances VT3989 toward a…
Eascra Biotech announced Andrew Goodearl, Ph.D., as chief scientific officer, adding an executive with biotherapeutics and genetic-medicine research experience to the early-stage nanomedicine company. The company did not identify a predecessor, appointment effective date,…
